Skip to main content

and
  1. Article

    Open Access

    Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study

    Adjuvant chemotherapy is the standard of care in high-risk early breast cancer patients. Dose-dense should be the preferred schedule of administration. However, its long-term benefit is unknown.

    Eva Blondeaux, Matteo Lambertini, Andrea Michelotti in British Journal of Cancer (2020)